Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

66.98 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
34 35 Next >
3 Desirable Drug Stocks With Very Promising Pipelines
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider. 
Via InvestorPlace
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Q4 Revenue, FY22 Sales Outlook Lag Consensus
Bristol Myers Squibb & Co (NYSE: BMY) has posted  
Via Benzinga
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial
Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (... 
Via Benzinga
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
From Bristol Myers Squibb
Via Business Wire
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
Nuclear Winter
Mexico is raising interest rates to 6%, from 5.5%. 
Via Talk Markets
Daily Report: Bristol - Myers Squibb (BMY)
Bristol's price per share was $66.50 as of yesterday's market close. One year ago its price was $59.99. 
Via Talk Markets
6 Companies That Recently Announced Large Buybacks
There are several ways that a company can return wealth to its shareholders. Price appreciation and dividends are the two most common ways, but there are other ways a company... 
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements
From Bristol Myers Squibb
Via Business Wire
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch
Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century... 
Via Benzinga
Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.
From Bristol Myers Squibb
Via Business Wire
Looking At Bristol-Myers Squibb's Recent Whale Trades
A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 17 strange trades. 
Via Benzinga
Stock Market Rally Volatile; Google, Facebook, Amazon, Snap Are Earnings Movers: Weekly Review
The major indexes slashed weekly gains after Monday's follow-through day. 
Via Investor's Business Daily
5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet
Joe Biden is redoubling his efforts to fight cancer with a new "cancer cabinet." Here are the biotech stocks to buy that can benefit. 
Via InvestorPlace
Bristol Myers Squibb (BMY) Q4 Earnings Meet Estimates
Bristol Myers Squibb came out with quarterly earnings of $1.83 per share. 
Via Talk Markets
Bristol Myers Ekes Out Earnings Beat As Cancer Drugs Spur Growth
The best growth during the quarter came from a blood thinner, an anemia treatment and cancer drugs. 
Via Investor's Business Daily
ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb: Q4 Earnings Insights
  Bristol-Myers Squibb (NYSE:BMY) reported its Q4 earnings results on Friday, February 4, 2022 at 06:59 AM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
From Bristol Myers Squibb
Via Business Wire
5 Stocks To Watch For February 4, 2022
Some of the stocks that may grab inve3stor focus today are: Wall Street expects Bristol-Myers Squibb Company (NYSE: BMY) to report quarterly earnings at $1.80 per share on revenue of $12.08 billion... 
Via Benzinga
Earnings Scheduled For February 4, 2022
Companies Reporting Before The Bell • Brookfield Business (NYSE:BBU) is estimated to report earnings for its fourth quarter. 
Via Benzinga
Facebook FB plunges but Amazon AMZN surges: Earnings and Your Updated Price Levels
It seems like yesterday we were discussing the surge in Alphabet shares, and today we're focusing on big moves - currently in opposite directions - of Facebook and Amazon, all major market cap... 
Via Talk Markets
Earnings Outlook For Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE:BMY) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?
Photo by Diana Polekhina on Unsplash 
Via Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.